摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
* n- c8 ?; E7 w5 N# P% |, `, y; ^ 关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
" V$ z6 ?% S; U8 K# M 5 d T7 d3 q5 }6 I% @5 U
作者：来自澳大利亚: p' D: Q L6 P3 B
来源：Haematologica. 2011.8.9.
. _3 q+ o) W: V" s: tDear Group,. D" K; F" B, b
0 ^& C7 ^( b: W- W: g6 V" z/ rSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
+ G! D! V* i4 Q9 Ntherapies. Here is a report from Australia on 3 patients who went off Sprycel
3 ^9 i+ h3 I3 i2 F; Zafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
( ]9 q) c. z4 w, z Bremain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel5 }' |7 e, g0 j3 n7 e
does spike up the immune system so I hope more reports come out on this issue.% t y3 A% H z# m/ n
* z9 m$ L1 E; O4 ~9 @( ^4 xThe remarkable news about Sprycel cessation is that all 3 patients had failed
c" P- v0 a9 E4 f9 a6 bGleevec and Sprycel was their second TKI so they had resistant disease. This is: W/ Y1 i+ G4 N' d* a. X4 G6 b
different from the stopping Gleevec trial in France which only targets patients
: q r% p. I/ I" `9 qwho have done well on Gleevec.# ~' E% a( @1 [& _
5 \8 G. n# s# @& L. J) xHopefully, the doctors will report on a larger study and long-term to see if the! f, r, T$ c, t8 z3 u4 D1 T+ @5 L
response off Sprycel is sustained. S% r. |& M" b" G6 C$ @
7 i" K. Q8 {5 w E+ g, Q( r
Best Wishes,
0 H, _$ w# ]$ s CAnjana
' f' _; e; ~. L2 i3 B7 H4 Y
* K9 J* a! K2 Q3 V m8 g; m; x/ ^# A0 q/ m3 p5 o
- p1 M, {* {- R) ZHaematologica. 2011 Aug 9. [Epub ahead of print]
0 c4 j6 I! Z# ?3 w ?' T# @Durable complete molecular remission of chronic myeloid leukemia following2 O% }& B: P& F7 H5 H+ m$ J o
dasatinib cessation, despite adverse disease features.
# e/ F. }3 E" O7 b vRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.- N% ^" z4 S- I$ o; ~
Source
4 s' f5 Z. S! AAdelaide, Australia;
9 H2 R9 p" L7 T' W Y" d1 X8 r: `0 B6 S- Y* T8 S* V* ^1 N& H
Abstract; X- s9 C3 ?/ o8 \; _ y
Patients with chronic myeloid leukemia, treated with imatinib, who have a, i" M% W, T4 B) f
durable complete molecular response might remain in CMR after stopping
3 ]' X+ N* R' s0 mtreatment. Previous reports of patients stopping treatment in complete molecular# t9 V/ w* d- v9 A
response have included only patients with a good response to imatinib. We0 _8 J L9 ^8 Y2 {7 C
describe three patients with stable complete molecular response on dasatinib
2 o* \1 o1 S& ^1 k! K7 Ttreatment following imatinib failure. Two of the three patients remain in6 V# E! y5 w* k& W% @
complete molecular response more than 12 months after stopping dasatinib. In. l0 r' Q& o# r$ W0 z7 |) t
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
1 s# j! B' d/ Rshow that the leukemic clone remains detectable, as we have previously shown in
( U) _ v* G9 B3 ?/ _imatinib-treated patients. Dasatinib-associated immunological phenomena, such as; ^1 y) r; c3 S5 O
the emergence of clonal T cell populations, were observed both in one patient
% K/ O' A; M6 m- q2 Dwho relapsed and in one patient in remission. Our results suggest that the' }2 r* V) W3 U* A2 U. s
characteristics of complete molecular response on dasatinib treatment may be
; z0 W" D: @, F4 j! Z' Ksimilar to that achieved with imatinib, at least in patients with adverse, n7 R/ n& o! ?: ]
disease features.( I/ g' z0 i, T w g
|
显身卡
